Login | Register

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Identifier: NCT05256225

Clinical trials are currently being offered at Medical University of South Carolina (MUSC) Health Care in Charleston SC.

A Phase II/III Study of Paciltaxel/Carboplatin alone, or combined with either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA), or combined with Trastuzumab and Hyaluronidase-zzfx (PHESCO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma OR Endometrial Carcinosarcoma.

Sponsor: NRG, Sponsor Study ID: GY026
NCT Number: NCT05256225
Phase: II/III
Protocol Type: Treatment
Age Group: Adults

Study Objectives: This Phase II/III trial tests whether adding Trastuzumab and Hyaluronidase-cysk, OR, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf to the usual chemotherapy (Pacitaxel and Carboplatin) works to shrink tumors in patients with HER2 positive Endometrial Serous Carcinoma or Endometrial Carcinosarcoma.
Study Documents: (https://portal.musc.edu/hcc/cto/WebDocs/103749).

The MUSC Resource telephone number to call about this study is: 843-985-0580.

Please see the National Institute of Health’s ClinicalTrials.gov site for more information.